Quality-by-design in pharmaceutical development : From current perspectives to practical applications
© 2021 Béla Kovács et al., published by Sciendo..
Current pharmaceutical research directions tend to follow a systematic approach in the field of applied research and development. The concept of quality-by-design (QbD) has been the focus of the current progress of pharmaceutical sciences. It is based on, but not limited, to risk assessment, design of experiments and other computational methods and process analytical technology. These tools offer a well-organized methodology, both to identify and analyse the hazards that should be handled as critical, and are therefore applicable in the control strategy. Once implemented, the QbD approach will augment the comprehension of experts concerning the developed analytical technique or manufacturing process. The main activities are oriented towards the identification of the quality target product profiles, along with the critical quality attributes, the risk management of these and their analysis through in silico aided methods. This review aims to offer an overview of the current standpoints and general applications of QbD methods in pharmaceutical development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Acta pharmaceutica (Zagreb, Croatia) - 71(2021), 4 vom: 01. Dez., Seite 497-526 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kovács, Béla [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 18.01.2023 published: Electronic-Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2478/acph-2021-0039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351623558 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351623558 | ||
| 003 | DE-627 | ||
| 005 | 20231226051832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2478/acph-2021-0039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1172.xml |
| 035 | |a (DE-627)NLM351623558 | ||
| 035 | |a (NLM)36651549 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kovács, Béla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality-by-design in pharmaceutical development |b From current perspectives to practical applications |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.01.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Béla Kovács et al., published by Sciendo. | ||
| 520 | |a Current pharmaceutical research directions tend to follow a systematic approach in the field of applied research and development. The concept of quality-by-design (QbD) has been the focus of the current progress of pharmaceutical sciences. It is based on, but not limited, to risk assessment, design of experiments and other computational methods and process analytical technology. These tools offer a well-organized methodology, both to identify and analyse the hazards that should be handled as critical, and are therefore applicable in the control strategy. Once implemented, the QbD approach will augment the comprehension of experts concerning the developed analytical technique or manufacturing process. The main activities are oriented towards the identification of the quality target product profiles, along with the critical quality attributes, the risk management of these and their analysis through in silico aided methods. This review aims to offer an overview of the current standpoints and general applications of QbD methods in pharmaceutical development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a pharmaceutical development | |
| 650 | 4 | |a quality-by-design | |
| 650 | 4 | |a risk assessment | |
| 650 | 4 | |a software-aided development | |
| 700 | 1 | |a Péterfi, Orsolya |e verfasserin |4 aut | |
| 700 | 1 | |a Kovács-Deák, Boglárka |e verfasserin |4 aut | |
| 700 | 1 | |a Székely-Szentmiklósi, István |e verfasserin |4 aut | |
| 700 | 1 | |a Fülöp, Ibolya |e verfasserin |4 aut | |
| 700 | 1 | |a Bába, László-István |e verfasserin |4 aut | |
| 700 | 1 | |a Boda, Francisc |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmaceutica (Zagreb, Croatia) |d 1997 |g 71(2021), 4 vom: 01. Dez., Seite 497-526 |w (DE-627)NLM092561411 |x 1846-9558 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2021 |g number:4 |g day:01 |g month:12 |g pages:497-526 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2478/acph-2021-0039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2021 |e 4 |b 01 |c 12 |h 497-526 | ||